LEAP2 and type 2 diabetes mellitus: Thus the discovery of the endogenous inverse agonist LEAP2 may reveal potential therapeutic targets for gastric hunger-related diseases, including type 2 diabetes and obesity, as it interacts with gastric hunger and is expressed at elevated levels after RYGB surgery (115).